
zzso zzso zzso is a zzso zzso zzso zzso that acts primarily at the cell membrane targeting signal zzso zzso Early clinical trials were limited because of zzso gastrointestinal zzso and zzso dosing of this class of agents is not possible because of their zzso zzso therefore, related compounds with an improved therapeutic index were zzso zzso was minimized and efficacy improved by using a loading zzso dose schedule, and therefore, this schedule was carried into clinical zzso This phase I trial enrolled 42 patients with incurable solid zzso The starting doses were 100 zzso zzso zzso four doses zzso 6 zzso load followed by a 50 zzso zzso once daily maintenance dose with escalation of either component in successive dose zzso No treatment related deaths zzso The zzso dose was determined to be 150 zzso zzso zzso four doses load and 100 zzso zzso once daily zzso zzso zzso such as zzso zzso dehydration, and fatigue were seen early during the loading phase and were zzso with the use of zzso zzso zzso antagonists, zzso and zzso zzso during the chronic phase were difficult to manage and, given that zzso data showed biologically active serum zzso (based on zzso zzso raised the question of less frequent maintenance zzso zzso data confirmed the maintenance of stable drug levels with chronic dosing and the long zzso One partial response was seen, as were multiple patients with stable disease beyond course zzso These results suggest zzso activity in zzso and perhaps zzso cell zzso zzso disease in two patients who continued for 6 and 14 zzso thus zzso additional investigation of this agent in a phase II zzso zzso 

